Although a subset of ~17.9% of AciCCs has been reported to express EGFR [55], only few clinical trials regarding anti-EGFR therapy in salivary gland carcinomas have been performed and the treatment did not result in significant clinical responses so far [55,56]. This evidence concerns the gene EGFR and salivary gland carcinoma.